Pomalyst
Pomalidomide capsules for multiple myeloma. This is a newer generation of a drug class that works with the immune system to target myeloma cells.
- Category
- Oncology Support
- Active ingredient
- Pomalidomide
- Route
- Oral use
- Form
- Capsule, hard
- Strengths
- 4mg
This listing uses Pomalyst as a reference name. A generic equivalent is supplied; its exact brand and manufacturer are confirmed before supply.
Prescription and consultation requirements for Pomalyst vary by destination and are determined by the fulfilment partner.
Pomalyst details
- Condition
- Multiple Myeloma
- Alternative names
- Imnovid
- Therapeutic class
- Immunosuppressants; Other immunosuppressants
- Pharmacological class
- Immunomodulatory imide drug; Cereblon e3 ubiquitin ligase modulator
- Dosage forms
- Capsule, hard
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Originator
- Bristol-Myers Squibb Pharmaceuticals Limited
- Storage instructions
- Store below 25°C. Keep in the original blister package to protect from moisture.
Known off-label uses
primary central nervous system lymphoma; systemic light chain amyloidosis; myelofibrosis
Contraindications
hypersensitivity to pomalidomide or any excipient; women who are pregnant; women of childbearing potential unless all conditions of the pregnancy prevention programme are met
Precautions and warnings
pregnancy prevention programme mandatory for all patients; haematological toxicity including neutropenia, anaemia and thrombocytopenia requiring regular monitoring; venous thromboembolism risk requiring thromboprophylaxis; second primary malignancies; thyroid disorders including hypothyroidism; peripheral neuropathy; tumour lysis syndrome; cardiac disorders including myocardial infarction and cardiac failure; hepatic disorders; severe cutaneous reactions; allergic reactions including angioedema; risk of hepatitis b reactivation; dose adjustment required with strong cyp1a2 inhibitors; caution in patients with renal impairment requiring dose adjustment; caution in patients with hepatic impairment; progressive multifocal leukoencephalopathy reported; males must use condoms during treatment and for 7 days after discontinuation
Minor side effects
neutropenia; anaemia; thrombocytopenia; fatigue; pyrexia; peripheral oedema; nausea; diarrhoea; constipation; vomiting; decreased appetite; dyspnoea; cough; upper respiratory tract infection; pneumonia; back pain; bone pain; muscle spasms; arthralgia; peripheral neuropathy; headache; dizziness; tremor; rash; pruritus; insomnia; confusional state; hypercalcaemia; hypokalaemia; weight decreased; epistaxis
Moderate side effects
febrile neutropenia; severe thrombocytopenia with bleeding; deep vein thrombosis; pulmonary embolism; myocardial infarction; cardiac failure; atrial fibrillation; hepatic failure; stevens-johnson syndrome; toxic epidermal necrolysis; angioedema; tumour lysis syndrome; progressive multifocal leukoencephalopathy; hepatitis b reactivation; sepsis; pneumonia; acute kidney injury; pancreatitis
Serious side effects
signs of febrile neutropenia including fever, chills, sore throat, mouth ulcers, requires immediate medical attention; signs of venous thromboembolism including sudden chest pain, difficulty breathing, swelling or pain in one leg, requires immediate medical attention; signs of progressive multifocal leukoencephalopathy including confusion, vision changes, weakness on one side of body, requires immediate medical attention; signs of severe cutaneous reactions including widespread rash, blistering, peeling skin, requires immediate medical attention; signs of angioedema including swelling of face, lips, tongue or throat, requires immediate medical attention; signs of myocardial infarction including chest pain, shortness of breath, pain radiating to arm or jaw, requires immediate medical attention; signs of hepatic failure including jaundice, dark urine, confusion, abdominal swelling, requires immediate medical attention
Patient summary
Pomalidomide capsules for multiple myeloma. This is a newer generation of a drug class that works with the immune system to target myeloma cells.
Mechanism of action
Pomalyst contains pomalidomide, a medicine belonging to a class of drugs called immunomodulatory imide drugs. It works by attaching to a protein called cereblon within cells. This binding changes how the cell functions, causing cancer cells to stop dividing and to die. Pomalidomide also stimulates the body's immune system to attack myeloma cells and prevents the formation of new blood vessels that tumours need to grow. It is used in adults with multiple myeloma whose cancer has come back after or did not respond to previous treatments.
Drug interactions
ciprofloxacin; enoxacin; fluvoxamine; warfarin; apixaban; rivaroxaban; dabigatran; heparin; digoxin; bortezomib; dexamethasone; daratumumab; isatuximab; simvastatin; atorvastatin; rosuvastatin; carbamazepine; phenytoin; rifampicin; st. john's wort; grapefruit juice
Age restrictions
Safety and efficacy in children and adolescents below 18 years have not been established.
Pregnancy and breastfeeding
Pregnancy: Pomalidomide is contraindicated during pregnancy. It is structurally related to thalidomide and is expected to cause severe life-threatening birth defects. Women of childbearing potential must use effective contraception from at least 4 weeks before treatment, during treatment, and for at least 4 weeks after stopping. Breastfeeding: Must be discontinued during therapy.
What you will receive
Pomalyst is used here as a reference originator brand name to identify the medicine. We are not affiliated with the brand owner, and this listing does not offer the originator product.
- The supplied product is a generic equivalent containing Pomalidomide, not the originator brand shown as the reference.
- The exact generic brand, manufacturer and dispatch location are confirmed based on the product, destination and available manufacturer or partner warehouse.
- Check the final product details at checkout before confirming an order.